Aromatase in endometriosis and uterine leiomyomata

被引：124

作者：

Bulun, SE ^{[1
]}

Imir, G ^{[1
]}

Utsunomiya, H ^{[1
]}

Thung, S ^{[1
]}

Gurates, B ^{[1
]}

Tamura, M ^{[1
]}

Lin, ZH ^{[1
]}

机构：

[1] Northwestern Univ, Dept Obstet & Gynecol, Chicago, IL 60611 USA

来源：

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 2005年 / 95卷 / 1-5期

关键词：

aromatase; aromatase inhibitor; letrozole; anastrozole; endometriosis; uterine leiomyomata; estrogen; estrogen biosynthesis; endometrium; uterus;

D O I：

10.1016/j.jsbmb.2005.04.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Endometrial tissue from uterine disease-free women does not exhibit aromatase activity. In contrast, aromatase enzyme activity and mRNA levels are readily detectable in endometriosis. PGE(2) stimulates both aromatase expression and activity in endometriotic stromal cells via promoter II region of the aromatase gene. This results in local production of estradiol, which induces PGE(2) formation and establishes apositive feedback cycle. This mechanism seems to contribute to continuous production of estradiol and PGE(2). Aromatase mRNA levels and enzyme activity are also present in uterine leiomyomata that are estrogen-dependent benign tumors of the myometrium. Successful treatment of endometriosis and uterine leiomyomata using aromatase inhibitors by recent pilot trials underscores the clinical significance of these molecular studies. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：57 / 62

页数：6